		USD	INR (' In Thousands)	USD	INR (' In Thousands)
	,	As at		As a	t
	Notes	31 March	2018	31 Marc	h 2017
ASSETS					
Non-current assets					
Financial assets					
Investments	1.	1,371,501	89,381	1,371,501	88,942
Total non-current assets		1,371,501	89,381	1,371,501	88,942
Current assets					
Financial assets					
Cash and cash equivalents	2	1,306	85	1,306	85
Other current assets	3	3,208	209	3,096	201
Total current assets	2 1	4,514	294	4,402	286
Total assets	-	1,376,015	89,675	1,375,903	89,228
EQUITY AND LIABILITIES					
Equity					
Equity share capital	4	1,397,501	69,846	1,397,501	69,846
Other equity		(38,162)	18,742	(34,822)	18,524
Total equity	_	1,359,339	88,588	1,362,679	88,370
LIABILITIES					
Current liabilities					
Financial liabilities					
Trade payables	5	16,676	1,087	13,224	858
Total current liabilities	_	16,676	1,087	13,224	858
Total liabilities	=	16,676	1,087	13,224	858
Total equity and liabilities	_	1,376,015	89,675	1,375,903	89,228

Rajneesh Gupta Vice Presedent - Finance

Jubilant Biosys (BVI) Limited Statement of Profit and Loss for the year ended 31 March 2018

	USD	INR (' In Thousands)	USD	INR (' In Thousands)
Notes	For the year ende	d 31 March 2018	For the year ended	
6	3,340	215	3,529	237
	3,340	215	3,529	237
	(3,340	(215)	(3,529)	(237)
		5	-	
	(3,340	(215)	(3,529)	(237)
SS				
		433		(1,904)
ftax		433	7	(1,904)
	(3,34)	218	(3,529)	(2,141)
		Notes For the year ende 6 3,340 3,340 (3,340)	Thousands) Notes For the year ended 31 March 2018 6 3,340 215 3,340 215 (3,340) (215)	Thousands) Notes For the year ended 31 March 2018 For the year ended 6 3,340 215 3,529 3,340 215 3,529 (3,340) (215) (3,529) (3,340) (215) (3,529) SSS 433

Rajneesh Gupta Vice Presedent - Finance

		Reserves and surplus				
	Retaine	d earnings	Exchange differnces on translation of foreign operations	T	otal	
	USD	INR († In Thousands)	INR (' In Thousands)	USD	INR (' In Thousands)	
Balance as at 1 April 2016	(31,293)	15,530	5,135	(31,293)	20,665	
Loss for the year Exchange loss during the year on translation of foreign operations	(3,529)	(237)	(1.004)	(3,529)	, ,	
Balance as at 31 March 2017	(34,822)	15,293	(1,904) 3,231	(34,822)	(1,904) 18,524	
Loss for the year Exchange gain during the year on	(3,340)	(215)	18.	(3,340)	(215)	
translation of foreign operations	¥	:#S	433	-	433	
Balance as at 31 March 2018	(38,162)	15,078	3,664	(38,162)	18,742	

Rajneesh Gupta Vice Presedent - Finance

Jubilant Biosys (BVI) Limited Statement of Cash Flows for the year ended on 31 March 2018

	USD	INR (' In Thousands)	USD	INR (' In Thousands)
Particulars	•	er ended on 31 ch 2018	-	r ended on 31 ch 2017
A. Cash flow from operating activities				
Loss before tax	(3,340)	(215)	(3,529)	(237)
Operating cash flow before working capital changes				
Increase in other current assets	(112)) (7)	(1,473)	(99)
Increase in trade payables	3,452	222	4,937	331
Cash (used in) from operations	-	-	(65)	(5)
Income tax paid (net of refund)	390	:=0	-	16
Net cash used in operating activities	241	220	(65)	(5)
B. Effect of exchange rate changes		0		(1)
Net decrease in cash and cash equivalents (A+B)		0	(65)	(6)
Add: cash and cash equivalents at the beginning of year	1,306	85	1,371	91
Cash and cash equivalents at the end of the year	1,306	85	1,306	85

Rajneesh Gupta Vice Presedent - Finance

Jubilant Biosys (BVI) Limited

Notes to the financial statements for the year ended 31 March 2018

Note 1. Non-current investments
Jubilant Biosys (Singapore) Pte Ltd
1,371,501 (31 March 2017: 1,371,501 equity shares with no par value)

Note 2. Cash and cash equivalents

Balances with banks:

- On current accounts

Note 3. Other current assets Prepaid expenses

USD	INR (' In Thousands)	USD	INR (' In Thousands)	
As at 31 Ma		As at 31 Ma		
1,371,501	89,381	1,371,501	88,942	
1,371,501	89,381	1,371,501	88,942	
1,306	85	1,306	85	
1,306	85	1,306	85	
3,208	209	3,096	201	
3,208	209	3,096	201	

Jubilant Biosys (BVI) Limited Statement of Changes in Equity for the year ended 31st March 2018

Note 4: Equity share ca	ınıtal	
-------------------------	--------	--

		INR (' In		INR (' In
	USD	Thousands)	USD	Thousands)
	As at 31 N	March 2018	As at 31	March 2017
Issued, subscribed and paid up equity share capital				
1,397,501 (31 March 2017: 1,397,501 equity of USD 1 each	1,397,501	69,846	1,397,501	69,846
	1,397,501	69,846	1,397,501	69,846
Movement in equity share capital				
	Note	No. of shares	USD	INR (' In Thousands)
Balance as at 1 April 2016	4	1,397,501	1,397,501	69,846
Changes in equity share capital during the year			(*c	
Balance as at 31 March 2017	4	1,397,501	1,397,501	69,846
Changes in equity share capital during the year				
Balance as at 31 March 2018	4	1,397,501	1,397,501	69,846

The Company has only one class of shares referred to as equity shares having par value of USD 1 each, Each holder of equity shares is entitled to one vote per share. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company, after distribution of all preferential amounts. However, no such preferential amounts exist currently. The distribution will be in proportion to the number of equity shares held by the shareholders.

The details of shareholders holding more than 5% shares in the company:-

	USD	INR (' In Thousands)	USD	INR (' In Thousands)
	As 31-Ma			s at Iar-17
	No of shares	% holding in the class	No of shares	% holding in the class
Jubilant Life Sciences (BVI) Limited	1,397,501	100%	1,397,501	100%

Jubilant Biosys (BVI) Limited Notes to the financial statements for the year ended 31 March 2018

Note 5. Trade payables

Trade payables-others

USD	INR (' In Thousands)	USD	INR (' In Thousands)
As at 31 March 2018		As at 31 March 2017	
16,676	5 1,087	13,224	858
16,676		13,224	858

Jubilant Biosys (BVI) Limited Notes to the financial statements for the year ended 31 March 2018

Note 6. Other expense Legal, professional and consultancy charges Bank charges

USD	INR (' In	USD	INR (' In
	Thousands)		Thousands)
For the ye	ar ended	For the yea	r ended
31 Marc	h 2018	31 March 2017	
3,340	215	3,464	233
-	723	65	
3,340	215	3,529	237